Literature DB >> 1086622

Clinical, epidemiologic, and pulmonary function studies in alpha,-antitrypsin-deficient subjects of Pi Z type.

W Rawlings, P Kreiss, D Levy, B Cohen, H Menkes, S Brashears, S Permutt.   

Abstract

The results of pulmonary function testing and systematic medical history and epidemiologic data collection are reported for 20 persons with alpha 1-antitrypsin deficiency of Pi Z phenotype. The most common symptom, reported in 19 subjects (95 per cent), was dyspnea on exertion; 16 subjects (80 per cent) gave a history of wheezing, and 8 (40 percent) reported chronic cough and sputum production. The 8 women who had been pregnant reported a miscarriage rate of 29 per cent for all pregnancies. Respiratory symptoms and disease were commonly reported in the children of study subjects. Pulmonary function testing revealed abnormalities for 18 of 20 subjects, all of those 26 or more years of age. The test that was most frequently abnormal was the 1-sec forced expiratory volume expressed as a per cent of the forced vital capacity. All pulmonary function studies demonstrated a trend toward increased impairment with increased age, which was evident by the fourth decade. Within this group of persons having severe alpha1-antitrypsin deficiency, there was no correlation between serum concentrations of antitrypsin and subjective or objective indices of pulmonary disease. A group of 7 subjects who were incidentally found to have Pi Z alpha1-antitrypsin deficiency exhibited symptoms and pulmonary function abnormalities comparable to those of 13 subjects who were originally referred for known or suspected pulmonary disease. These data suggest that if interventions such as smoking cessation and occupational counseling are to be effective, they should be initiated before the fourth decade of life.

Entities:  

Mesh:

Year:  1976        PMID: 1086622     DOI: 10.1164/arrd.1976.114.5.945

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  4 in total

1.  Homozygous alpha1 antitrypsin deficiency with unusual associations: a case report.

Authors:  R C Young; V E Headings; S Bose; R L Hackney
Journal:  J Natl Med Assoc       Date:  1978-02       Impact factor: 1.798

2.  Protease inhibitor profile of black Americans with and without chronic cardiopulmonary disease.

Authors:  R C Young; V E Headings; A L Henderson; S Bose; R L Hackney
Journal:  J Natl Med Assoc       Date:  1978-11       Impact factor: 1.798

3.  Assessment of alpha-1-antitrypsin deficiency heterozygosity as a risk factor in the etiology of emphysema. Physiological comparison of adult normal and heterozygous protease inhibitor phenotype subjects from a random population.

Authors:  D J McDonagh; S P Nathan; R J Knudson; M D Lebowitz
Journal:  J Clin Invest       Date:  1979-02       Impact factor: 14.808

4.  Limited proteolysis by macrophage elastase inactivates human alpha 1-proteinase inhibitor.

Authors:  M J Banda; E J Clark; Z Werb
Journal:  J Exp Med       Date:  1980-12-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.